These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 9743354

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Constitutive expression of high levels of soluble mouse CD4 in transgenic mice does not interfere with their immune function.
    Weber S, Traunecker A, Karjalainen K.
    Eur J Immunol; 1993 Feb; 23(2):511-6. PubMed ID: 8094673
    [Abstract] [Full Text] [Related]

  • 44. Combining positional scanning peptide libraries, HLA-DR transfectants and bioinformatics to dissect the epitope spectrum of HLA class II cross-restricted CD4+ T cell clones.
    Sospedra M, Zhao Y, Giulianotti M, Simon R, Pinilla C, Martin R.
    J Immunol Methods; 2010 Feb 28; 353(1-2):93-101. PubMed ID: 20036243
    [Abstract] [Full Text] [Related]

  • 45. Selection and function of CD4+ T lymphocytes in transgenic mice expressing mutant MHC class II molecules deficient in their interaction with CD4.
    Gilfillan S, Shen X, König R.
    J Immunol; 1998 Dec 15; 161(12):6629-37. PubMed ID: 9862691
    [Abstract] [Full Text] [Related]

  • 46. HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen.
    Rosloniec EF, Whittington KB, Zaller DM, Kang AH.
    J Immunol; 2002 Jan 01; 168(1):253-9. PubMed ID: 11751969
    [Abstract] [Full Text] [Related]

  • 47. Peptide binding to soluble HLA-DR4 molecules produced by insect cells.
    Scheirle A, Takacs B, Kremer L, Marin F, Sinigaglia F.
    J Immunol; 1992 Sep 15; 149(6):1994-9. PubMed ID: 1387668
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Mutations in human CD4 impair the functional interaction with different human and mouse class II isotypes and alleles.
    Fleury S, Huang B, Zerbib A, Croteau G, Long EO, Sekaly RP.
    J Immunol; 1996 Mar 01; 156(5):1848-55. PubMed ID: 8596036
    [Abstract] [Full Text] [Related]

  • 50. HLA class II transgenic mice: models of the human CD4+ T-cell immune response.
    Sønderstrup G, Cope AP, Patel S, Congia M, Hain N, Hall FC, Parry SL, Fugger LH, Michie S, McDevitt HO.
    Immunol Rev; 1999 Dec 01; 172():335-43. PubMed ID: 10631958
    [Abstract] [Full Text] [Related]

  • 51. Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice.
    Sakurai Y, Brand DD, Tang B, Rosloniec EF, Stuart JM, Kang AH, Myers LK.
    Arthritis Res Ther; 2006 Dec 01; 8(5):R150. PubMed ID: 16982003
    [Abstract] [Full Text] [Related]

  • 52. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C, Newman DK, Bohlen H, König A, Koch N.
    Int Immunol; 2000 Nov 01; 12(11):1561-8. PubMed ID: 11058576
    [Abstract] [Full Text] [Related]

  • 53. Visualization of the human CD4⁺ T-cell response in humanized HLA-DR4-expressing NOD/Shi-scid/γc(null) (NOG) mice by retrogenic expression of the human TCR gene.
    Takahashi T, Katano I, Ito R, Ito M.
    Biochem Biophys Res Commun; 2015 Jan 02; 456(1):219-24. PubMed ID: 25462565
    [Abstract] [Full Text] [Related]

  • 54. Identification of HLA-DR4-restricted immunogenic peptide derived from xenogenic porcine major histocompatibility complex class I molecule.
    Park CS, Kim KH, Im SA, Song S, Lee CK.
    Xenotransplantation; 2012 Jan 02; 19(5):317-22. PubMed ID: 22978463
    [Abstract] [Full Text] [Related]

  • 55. Multiple regions of HLA-DR beta 1 chains determine polymorphic epitopes recognized by monoclonal antibodies.
    Alber CA, Watts R, Klohe EP, Drover S, Marshall WH, Radka SF, Karr RW.
    J Immunol; 1989 Oct 01; 143(7):2248-55. PubMed ID: 2476501
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. T cell selection and differential activation on structurally related HLA-DR4 ligands.
    Gebe JA, Novak EJ, Kwok WW, Farr AG, Nepom GT, Buckner JH.
    J Immunol; 2001 Sep 15; 167(6):3250-6. PubMed ID: 11544312
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.